摘要
目的观察拉米夫定联合胸腺肽α1治疗慢性乙型肝炎的疗效。方法拉米夫定联合胸腺肽α1治疗24周后检查HBV-M及肝功能,并与对照组比较。结果治疗组肝功能好转,与对照组比较差异有统计学意义(P<0.05);HBeAg、HBV-DNA转阴率治疗组与对照组比较差异有统计学意义(P<0.05)。结论拉米夫定联合胸腺肽α1治疗慢性乙型肝炎效果肯定。
Objective To observe the therapy effect of Lamivudine combined with thymic peptide-α 1 on hepatitis B. Methods After 24 week treatment by using Lamivudine combined with thymic peptide-α1,the HBV-M and liver functions were examined and compared between the treatment group and the control group. Results The liver functions of the treatment group turned better compared with the control group, with a significant difference between the two groups（P〈0.05 ）, and there was a significant difference in the negative rates of HBeAg and HBV-DNA between the two groups （ P〈 0.05 ）. Conclusion Combination of Lamivudine with thymic peptide- α 1 is very effective in the treatment of hepatitis B.
出处
《中国现代医生》
2009年第31期60-61,共2页
China Modern Doctor
关键词
拉米夫定
联合
胸腺肽Α1
肝功能
乙肝病毒标志物
Lamivudine
Combination
Thymic peptide-α1
Liver function
Hepatitis B virus markers.
